Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
XETRA:6MK
6MK Stock Chart & Stats
€86.30
€0.40(0.41%)
At close: 4:00 PM EST
€86.30
€0.40(0.41%)
Day’s Range― - ―
52-Week Range€65.50 - €99.40
Previous CloseN/A
Volume75.00
Average Volume (3M)4.24K
Market Cap
$212.54B
Enterprise Value€232.84B
Total Cash (Recent Filing)$18.21B
Total Debt (Recent Filing)$41.37B
Price to Earnings (P/E)12.6
Beta0.57
Next Earnings
Feb 03, 2026EPS Estimate
1.76Next Dividend Ex-Date
Dec 15, 2025Dividend Yield3.33%
Share Statistics
EPS (TTM)2.22
Shares Outstanding2,482,022,500
10 Day Avg. Volume3,962
30 Day Avg. Volume4,243
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.44
Price to Sales (P/S)3.93
P/FCF Ratio13.92
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue3.62
Enterprise Value/Gross Profit4.63
Enterprise Value/Ebitda8.45
Forecast
1Y Price Target
$93.98Price Target Upside8.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMerck reported earnings with a slight beat on the topline and a larger beat on EPS, driven by stronger sales in key areas.
Product InnovationMerck's doravirine/islatravir (DOR/ISL) is just as effective at suppressing HIV replication compared to Gilead's regimen, providing greater HIV therapeutic regimen optionality.
Strategic AcquisitionsMerck makes another reasonable acquisition: Cidara, with the lead asset CD388, designed for flu prevention with high efficacy rates.
Bears Say
Expense ManagementThere is an expected acceleration in operating expenses in 2026 driven by investment in R&D and SG&A to fuel pipeline and new launches.
Product PerformanceMisses for Winrevair do not help assuage concerns of the upcoming Keytruda LOE.
Revenue GuidanceGuidance for FY25 revenue was narrowed and slightly revised down, adding pressure to future performance expectations.
Merck & Company News
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €65.50 and its highest was €99.40 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $212.54B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Feb 03, 2026 which is in 57 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Oct 30, 2025. The company reported €2.215 earnings per share for the quarter, beating the consensus estimate of €2.028 by €0.187.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €0.73 which represents an annual dividend yield of 3.33%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 1.76.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,482,022,500 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €2.215 in its last earnings report, beating expectations of €2.028. Following the earnings report the stock price went down -0.802%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in DE:6MK
Merck & Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$93.98 (8.89% Upside)
$93.98 (8.89% Upside)
Blogger Sentiment
Bullish
DE:6MK Sentiment 89%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.13%
12-Months-Change
Fundamentals
Return on Equity
39.51%
Trailing 12-Months
Asset Growth
10.22%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
6MK Company Deck
6MK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook, with strong performance in key segments like Oncology and significant pipeline advancements. Challenges were noted in GARDASIL sales and certain product launches, but the strategic acquisition of Verona Pharma and robust pipeline developments indicate a strong future trajectory.View all DE:6MK earnings summaries6MK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
6MK Stock 12 Month Forecast
Average Price Target
€93.98
▲(8.89% Upside)
Technical Analysis
Options Prices
Currently, No data available
---